BofA Terminates Coverage On Tilray, Aurora Cannabis

On November 18th, Bank of America terminated coverage on Tilray Inc (TSX: TLRY) and Aurora Cannabis (TSX: ACB), citing a reallocation of resources while slashing their price targets on Canopy and Cronos. This comes after the licensed producers showed another weak quarter.

For the Tilray termination note, they add some colour going forward after the fiscal first quarter, saying that COVID sales headwinds are expected to persist. They believe this is the case since COVID-19 had impacted store sales, with Ontario opening their stores up again at full capacity just recently. They write, “COVID concerns are impacting the consumer behavior and weighing on traffic” and believe that the provinces are just starting to replenish their inventories.

Lastly, on Tilray, Bank of America believes Tilray will see the rest of the merger synergies into the second half of the company fiscal year. They note that Tilray realized $55 million of its targeted $80 million in merger synergies.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

BofA also comments that Tilray saw $8 million in cash savings for the quarter, all in selling, general and administrative costs. They believe that about 30% of all synergies will flow through the cost of goods sold and write, “we assume a benefit starting in F2H now that the company has turned through legacy-Tilray inventory.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

This Gold Explorer Is Making Its Biggest Bet | Brian Miller – Astra Exploration

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

BMO: Netflix Is Now “Growth At A Reasonable Price”

The earnings season has started off with a bang as Netflix (Nasdaq: NFLX) closed its...

Wednesday, April 20, 2022, 04:45:47 PM

Antibe Therapeutics: Canaccord Upgrades Price Target To $16.50

Earlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm...

Thursday, February 11, 2021, 04:07:00 PM

Curaleaf: Cormark Upgrades To Buy Rating, Canaccord, Haywood Raise Price Targets

After Curaleaf’s (CSE: CURA) record-breaking second-quarter numbers, analysts have upgraded their twelve-month price targets. Curaleaf...

Wednesday, August 19, 2020, 11:29:55 AM

Snowflake: Canaccord Expects Long Term Guidance Of $10 Billion In Revenues To Remain Intact

Snowflake (NYSE: SNOW) last week reported its third-quarter financial results. The company announced that product...

Sunday, December 4, 2022, 01:24:00 PM

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM